Scarica l'app Stockscreener
48.41
1.19%
0.57
Dopo l'orario di chiusura:
48.36
-0.05
-0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)? - Yahoo Finance
Naked monoclonal antibodies Market in 2025-2032 Detailed Study - openPR.com
Bristol Myers Bets Billions on Chinese-Discovered Antibody for Cancer - Caixin Global
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific... - Medical Dialogues
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Bristol Myers (BMY) Teams Up with BioNTech to Advance Cancer The - GuruFocus
Bristol Myers (BMY) Teams Up with BioNTech to Advance Cancer Therapy | BMY Stock News - GuruFocus
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol-Myers Squibb’s Strategic Partnership with BioNTech: A Promising Future for BNT327 in Immunology Therapy - TipRanks
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field - Fierce Biotech
BioNTech, Bristol Myers Squibb form $11B cancer therapy alliance - Türkiye Today
Super deal for BioNTech – BMS licenses potential blockbuster for €10bn - European Biotechnology Magazine
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership - MSN
Bristol-Myers Squibb Stock: Is BMY Outperforming The Healthcare Sector? - Barchart.com
BioNTech (NasdaqGS:BNTX) Enters Global Co-Development Agreement With Bristol Myers Squibb - simplywall.st
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug - MSN
Bristol Myers Collaborates With BNTX for Oncology Candidate - The Globe and Mail
Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment - simplywall.st
Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal - NJBIZ
BioNTech and BMS partner to advance oncology deal worth over $10 billion - European Pharmaceutical Review
Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up - Yahoo Finance
American Bristol-Myers acquires license for innovative drug from German BioNTech for $11.1 billion - AKM.RU
BioNTech, Bristol Myers Squibb Team Up on China-Made Cancer Drug - Yicai Global
BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers - MedCity News
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies - Insider Monkey
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+ - BioWorld MedTech
Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space - insights.citeline.com
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet - CNBC
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy - The Economic Times
Bristol Myers signs deal worth up to $11.1 billion with BioNTech to develop cancer drug - MSN
Bristol Myers (BMY) Deal Seen as Highly Positive for BioNTech | - GuruFocus
BioNTech SE’s Strategic Partnership with Bristol Myers Squibb Boosts Financial Prospects and Reinforces Buy Rating - TipRanks
Bristol-Myers (BMY) Licenses BioNTech’s Immunotherapy in $11 billion Deal - Insider Monkey
Bristol Myers (BMY) Joins BioNTech in Promising Co-Development A - GuruFocus
Bristol Myers (BMY) and BioNTech Strike $11.1B Licensing Deal for Cancer Therapy - GuruFocus
BMS acquires rights to BioNTech’s bispecific antibody candidate BNT327 - The Pharma Letter
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug - Pharmaceutical Technology
Raymond James maintains market perform rating on Bristol Myers Squibb stock - Investing.com Australia
Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug - GuruFocus
Citi maintains neutral rating on Bristol-Myers Squibb stock By Investing.com - Investing.com India
Bristol-Myers to Pay $11 Billion to License Cancer Drug - Yahoo Finance
Watch Bristol-Myers to Pay $11 Billion to License Cancer Drug - Bloomberg.com
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration - Investopedia
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug - Yahoo Finance
Citi maintains neutral rating on Bristol-Myers Squibb stock - Investing.com
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific - BioSpace
Bristol Myers: signs global agreement with BioNTech - marketscreener.com
Bristol Myers inks $11B BioNTech deal to join bispecific gold rush, leaping ahead of Merck and Pfizer - Fierce Biotech
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race - MarketWatch
Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal - Yahoo Finance
Bristol Myers Squibb Partners with BioNTech in $1.5 Billion Deal to Develop Bispecific Cancer Drug Targeting PD1 and VEGF - geneonline.com
BioNTech, Bristol Myers partner to co-develop BNT327 - TipRanks
BioNTech Partners with Bristol Myers Squibb to Co-Develop Bispecific Antibody Drug BNT327 - marketscreener.com
BioNTech and Bristol Myers Squibb Partner for Global Development of BNT327 - TipRanks
Bristol Myers to help develop cancer drug in BioNTech partnership - BusinessLIVE
BioNTech soars 15% on cancer drug deal with Bristol Myers - StreetInsider
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb - WSJ
BioNTech soars 15% on cancer drug deal with Bristol Myers By Investing.com - Investing.com Nigeria
BioNTech, Bristol Myers Squibb to Co-Develop Bispecific Cancer Treatment - marketscreener.com
Bristol-Myers to Pay BioNTech Up to $11.1 Billion in Cancer Deal - Bloomberg.com
BioNTech soars premarket amid Bristol Myers deal - breakingthenews.net
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):